TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mortality in the different subtypes of patients
Endpoint domain: Mortality/survival
Primary endpoint: Disease outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Satisfaction with Overall Symptom Control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to hit the target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose Limited Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence and incidence of dysplasia and adenocarcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the curve of the glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Face Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digit Span (forward and backward)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants undergoing cardiac catheterization without subsequent procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Foot rotation angle error during stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of identification for enrolment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of Consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in number of lesions on face
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Protection against worsening of INO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on reading
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in the Hamilton Depression Rating Scale-17
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in national institute of health stroke score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Premature Ejaculation Diagnostic Tool score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grains consumption diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: meat consumption diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: poultry consumption diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fish consumption diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: flour consumption diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: vegetables consumption diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Remission rate of 24 hours urinary protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Global rating of change scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in pain reported by the participant during neck movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Sympathetic nervous system activity using skin conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in liver fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of subjects with treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with TEAEs by severity
Endpoint domain: Adverse events/effects
Primary endpoint: Persistence to endocrine therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sustained Return of Spontaneous Circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Free From a Major Device Event
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term safety of AA4500
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of diffusion-weighted MRI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Absence of Aneurysm Related Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Catecholamine norepinephrine and epinephrine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: LARS score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: biochemical failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of treatment with in vitro expanded autologous iNKT cells
Endpoint domain: Adverse events/effects
Primary endpoint: Forearm blood flow responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Score of the Functional Outcomes of Sleep Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Frequency of a greater than or equal to 4-fold rise in RSV-neutralizing antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: clinical severity scores in LUTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adapted Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Joint Specific Self-Reported Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Participant completion of MRI and Field measurements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of subjects achieving ACR20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Nerve Fiber Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Surrogate marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of chronic diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antibiotic sensitivity pattern of microbes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the concentration-time curve (AUClast) of Selpercatinib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Selpercatinib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach Cmax (Tmax) of Selpercatinib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Processed kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of a normalised control pHmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Number of Participants With Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Died Due to a Serious Adverse Event by Cause of Death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of vocal fold mobility impairment (VFMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Depression assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confusion assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Functional independence assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccines received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of Health Message
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual acuteness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomicroscopic exam with the slit lamp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Usability of inhaler devices
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Pelvic floor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area Under the Curve (AUC) for C-reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cutaneous LE Diseases Area and Severity Index (CLASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pseudoaneurysm
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Density of Hospital-acquired Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Relative change from baseline (%) of FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-operative neuropsychological state
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stroop Test for Executive Function - Inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: California Verbal Learning Test-II (CVLT-II) Total, Trials 1-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Digit Span, Forwards and Backwards
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: ADAMTS13 activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of Expert-confirmed HAE Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival free of atrial fibrillation
Endpoint domain: Mortality/survival
Primary endpoint: Mean Daytime Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Serum 25-hydroxyvitamin D (25-OHD) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence and incidence of anal HPV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of immediate hypersensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration (AUC, Cmax, tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index Percentile Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Injury
Endpoint domain: Adverse events/effects
Primary endpoint: adequacy rate of tissue sampling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Visual Blur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in peak oxygen consumption (peakVO2, in ml/kg/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in left ventricular dimension (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma glucose iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 100mm VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adequacy of pain treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Culture-positive patient drop-out
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative percentage drainage of SP2086 in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femur Head Necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Redislocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acetabular index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of SR13668
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Inhibition of uric acid crystallization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Thiosulfate in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thiosulfate in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sodium Sulfide in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-operative Endocrine Prognostic Index (PEPI Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: EndoPredict™ EPclin Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: percentage of patients with a favorable outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Hamilton Rating Scale for Depression (HRS-D17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Therapeutic effects of far infrared radiation on Hyperparathyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decrease of cytokines concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fidelity to daily relaxation breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective SUI cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence severity symptoms (ISS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinence impact symptoms (IIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in hamstring muscle extensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in unilateral hop for distance test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in crossover hop for distance tests scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessed by NCI-CTCAE scale
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of diabetic vascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Control rate of diabetes and diabetic vascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic use in 24 hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Change From Baseline in 24-hour Diastolic Ambulatory Blood Pressure Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change From Baseline in 24-hour Systolic Ambulatory Blood Pressure Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dyspnea BORG category score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day all cause readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Completion of SBIRT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Screened Positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referred to Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Marginal bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in mean glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in percentage of time in target blood glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in Eosinophils Per mL in Nasal Lavage Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Eosinophilic Cationic Protein Levels in Nasal Epithelial Lining Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Chemotherapy response assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between QFT-G IT assay and TST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Risk of latent TB infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Feasibility of the TachoSil® Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engineering development according to clinical assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fall-related injury
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of additional tumor-positive sentinel lymph nodes (SLNs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 6-Minutes Walk Test Distance (6MWTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG and/or electrogram changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary patency rate of the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percent Change in Free Testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Volatile Organic Chemical Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes of HbA1c (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of received supplemental oxygen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Brainstem Neural Activations to Capsaicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brainstem Neural Activations to ATP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum phosphorus change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Report 1 or More Adverse Events (AEs) - Healthy Participants
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Were Discontinued From the Study Due to an AE - Healthy Participants
Endpoint domain: Adverse events/effects
Primary endpoint: Change in 24-hour Time-weighted Average (TWA0-24hr) for Central Diastolic Blood Pressure (cDBP) - Healthy Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Participants With Local Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Corneal wavefront measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blastocyst rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentages for types I and III of the Rey figure copy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent time within therapeutic INR range 2-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-Stent Late Lumen Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extent of radioactivity eliminated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mammographic density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in vector mosquitoes entering houses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of chest wall tract metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Exposure to HDM201 and LEE011 as measured by AUC 0-24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TYMS (Thymidylate Synthetase) expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miRNA expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of PDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Empathic Accuracy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social Interactions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Anxiety and depression measure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Days alive and out of hospital within 14 days
Endpoint domain: Mortality/survival